Tracleer continues to fuel Actelion growth
pharmafile | February 19, 2010 | News story | Sales and Marketing |Â Â Actelion, TracleerÂ
Actelion has posted a 20% increase in revenue on the strength of its pulmonary hypertension treatment Tracleer.
The drug saw its sales rise 19% over the year, reaching CHF 1.51 billion ($1.39 billion).
Sales of Ventavis (iloprost), indicated for treatment of pulmonary arterial hypertension (PAH), amounted to CHF 136.9 million ($125 million), an increase of 44 per cent.
Sales of Zavesca (miglustat), indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease, grew to CHF 53.1 million ($48.8 million), an increase of 32 per cent.
Total net revenues reached CHF 1.77 billion ($1.63 billion).
Otto Schwarz, President Business Operations, Actelion said: “The strong growth momentum of Tracleer sales is remarkable, reflecting strong demand for innovative treatments in PAH as well as – in the EU – for the prevention of Digital Ulcerations in patients suffering from systemic scleroderma.
“Sales growth is also the result of our commercial efforts based on strong product labeling, strong relationships with key stakeholders, and excellence in execution on our competitive and market-building strategies.”
Chief executive Jean-Paul Clozel said: “Actelion has become a stronger company in 2009. The sales of our products continued to grow in an increasingly competitive environment. Our clinical pipeline continues to mature, with five compounds in advanced development stage.
“By focusing on innovation, we have created a wide range of growth opportunities. Our marketing and sales infrastructure in all key pharmaceutical markets worldwide, will allow us to generate best value for our existing and future products.”
Clozel continued: “I view the outlook for 2010 positively. I expect our existing business to continue to grow. I am looking forward to the results of our two pivotal phase III programmes reporting this year.”
Andrew J. Oakley, Chief Financial Officer forecasts that Actelion will continue in 2010 to leverage the growth platforms developed over the last few years. Excluding unforeseen events, Oakley believes that total net revenue growth in local currencies will be above 10 percent.
Related Content
Beyond Batten Disease Foundation partners with Actelion on development of combination treatment
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide …
Pharmafile.com’s top ten stories of 2017
After a packed year that has flown by, we’ve reached the final top ten of …
Actelion spin-off hit by blow shortly before buyout
Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it …
